Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX [Pharmacology]

Conclusions— Patients ≥75 years old have an overall 3-fold increased odds of moderate/severe bleeding. Cangrelor, when compared with clopidogrel, provides similar efficacy and in patients ≥75 years old as in those <75 years old but does not increase the risk of major bleeding. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique identifier: NCT01156571.

http://circinterventions.ahajournals.org/cgi/content/short/10/8/e005257?rss=1

Source: Circulation: Cardiovascular Interventions - August 11, 2017 Category: Cardiology Authors: Cavender, M. A., Bhatt, D. L., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Elkin, S., Deliargyris, E. N., Mahaffey, K. W., White, H. D., Harrington, R. A., on behalf of the CHAMPION PHOENIX Investigators* Tags: Anticoagulants, Percutaneous Coronary Intervention, Pharmacology Source Type: research